Neurotherapeutics in the Era of Translational Medicine Speaker: Richard A. Smith, M.D.
Director, Center for Neurologic Study
La Jolla, California
Friday, November 12, 12:00 p.m. to 1:00 p.m. CDT
Event Link: https://houstonmethodist.webex.com/houstonmethodist/j.php?MTID=macfa79ed611475ed2194b23edfc383d9
Access code: 2530 124 9830
Meeting password: MaFEGCwm653
Biogen and Ionis announced that BIIB080/IONIS-MAPTRx, an antisense drug, demonstrated robust time and dose-dependent lowering of tau protein in cerebrospinal fluid (CSF) over the three-month treatment period and sustained reductions during the six-month post-treatment period. Click here to learn more.
The lecture will be given in November at the Methodist Hospital (Houston). The invitation was extended by Dr. Stanley Appel, Chair of the Department of Neurology and Co-Director of the Methodist Neurological Institute.